Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

Conditions:   Pulmonary Alveolar Proteinosis;   COPD;   Idiopathic Pulmonary Fibrosis;   Viral Pneumonia;   Coronavirus Infection;   Interstitial Lung Disease Interventions:   Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF);   Device: Centricyte 1000;   Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution;   Drug: Liberase Enzyme (Roche);   Drug: Sterile Normal Saline for Intravenous Use Sponsors:   Healeon Medical Inc;   Robert W. Alexander, MD Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials